The Sanguine Difference
By simplifying the patient donation process, we have built a highly-engaged group of donors for minimally-invasive biospecimens.
Our Success In Numbers
2000+
Studies
Completed
15,000+
Home Visits Completed
25+
Top Pharma
Clients
100+
Nonprofit Organization Partnerships
70,000+
Patient Member Community
How the Legacy Indirect Model Stacks Up Against Ours
- Patient Access
Patient Centricity
Strategies for reach, recruitment, retention
Diversity of participant pool including hard-to-reach populations
Study participant recontact ability
Patient Community Access
Panoramic, long-term view of study participants
- Clinically Relevant Specimen + Data
Biospecimen procurement
Sample integrity
Biospecimen and data owner
Unique time-dependent insights (e.g., during disease-associated pain events, treatment response/nonresponse, peak and trough levels)
Longitudinal sampling
Simultaneous collection of multiple biospecimen types
Large volume blood specimen collection (≤180 mL)
Patient-reported outcomes data
Same-day sample collection and delivery
Renewable medical record-derived data
Us
Direct Patient Access
- Patient Access
-
Patient Centricity Engaged homegrown communities
-
Strategies for reach, recruitment, retention Mobile, virtual, flexible
-
Diversity of participant pool including hard-to-reach populations Unlimited by geographic reach and access to medical facility
-
Study participant recontact ability In-home
-
Patient Community Access Broad, multi-faceted
-
Panoramic, long-term view of study participants High retention, amendable study design, 95% patient retention rate
- Clinically Relevant Specimen + Data
-
Biospecimen procurement Yes
-
Sample integrity Yes
-
Biospecimen and data owner Yes
-
Unique time-dependent insights (e.g., during disease-associated pain events, treatment response/nonresponse, peak and trough levels)
Yes -
Longitudinal sampling
Yes -
Simultaneous collection of multiple biospecimen types Yes
-
Large volume blood specimen collection (≤180 mL) Yes
-
Patient-reported outcomes data Yes
-
Same-day sample collection and delivery Yes
-
Renewable medical record-derived data Yes
Biobanks
Indirect Patient Access
- Patient Access
-
Patient Centricity Third-party mediated, transactional
-
Strategies for reach, recruitment, retention Confined, brick and mortar
-
Diversity of participant pool including hard-to-reach populations Limited by geographic reach and access to medical facility
-
Study participant recontact ability Clinical collection center
-
Patient Community Access Oncology specialized
-
Panoramic, long-term view of study participants Low to no patient retention
- Clinically Relevant Specimen + Data
-
Biospecimen procurement No
-
Sample integrity No
-
Biospecimen and data owner No
-
Unique time-dependent insights (e.g., during disease-associated pain events, treatment response/nonresponse, peak and trough levels)
No
-
Longitudinal sampling
No -
Simultaneous collection of multiple biospecimen types No
-
Large volume blood specimen collection (≤180 mL) No
-
Patient-reported outcomes data No
-
Same-day sample collection and delivery No
-
Renewable medical record-derived data No

Access challenging, hard-to-collect samples
Sanguine's unique patient-centric approach to biospecimen collection gives researchers access to rare patient populations and complex study designs such as event-based collection, longitudinal collections, and more.
Are you a researcher?
Find out how Sanguine can accelerate your study.